Open AccessMetastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy.
Author(s) -
Rafał Turo,
Samer Jallad,
William Cross,
Stephen M. Prescott
Publication year - 2013
Publication title -
canadian urological association journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.477
H-Index - 38
eISSN - 1920-1214
pISSN - 1911-6470
DOI - 10.5489/cuaj.175
Subject(s) - medicine , prostate cancer , transsexual , transgender , incidence (geometry) , cancer , prostate , estrogen therapy , hormonal therapy , disease , hormone therapy , estrogen , oncology , gynecology , breast cancer , psychology , physics , psychoanalysis , optics
The incidence of prostate cancer in transsexual patients is very low with only few reported cases. Many years before presenting with prostate cancer, these patients receive hormone ablation as a part of their gender therapy. Their disease is already defined as castrate resistant, and the treatment and follow-up of such patients remains a challenge. We report a case of a male-to-female transgender woman who was diagnosed with metastatic prostate cancer, 31 years post-feminization.